|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
EBSCO_on1162314634 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
160307s2016 nyu ob 001 0 eng |
| 010 |
|
|
|a 2020677742
|
| 040 |
|
|
|a DLC
|b eng
|e rda
|c DLC
|d VLY
|d OCLCO
|d N$T
|d EBLCP
|d OCLCF
|d YDX
|d AGLDB
|d SNK
|d DKU
|d AUW
|d INTCL
|d MHW
|d BTN
|d IGB
|d D6H
|d VTS
|d AU@
|d G3B
|d SCB
|d S8J
|d S9I
|d STF
|d M8D
|d OCLCO
|d OCLCQ
|
| 019 |
|
|
|a 954215085
|
| 020 |
|
|
|a 9781634850438
|q (ebook)
|
| 020 |
|
|
|a 1634850432
|
| 020 |
|
|
|z 1634850386
|
| 020 |
|
|
|z 9781634850384
|
| 035 |
|
|
|a (OCoLC)1162314634
|z (OCoLC)954215085
|
| 050 |
0 |
0 |
|a RC271.C5
|
| 060 |
|
4 |
|a QZ 39
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
0 |
|a 616.99/4061
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
4 |
|a The easy book of cancer pharmacology /
|c Esther Una Cidon, editor.
|
| 246 |
3 |
0 |
|a Cancer pharmacology
|
| 264 |
|
1 |
|a New York :
|b Nova Biomedical,
|c [2016]
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Cancer Etiology, Diagnosis, and Treatments.; Pharmacology-Research, Safety Testing, and Regulation
|
| 490 |
1 |
|
|a Nova Biomedical
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a THE EASY BOOK OF CANCER PHARMACOLOGY; THE EASY BOOK OF CANCER PHARMACOLOGY; Library of Congress Cataloging-in-Publication Data; CONTENTS; FOREWORD; PREFACE; Chapter 1: ABIRATERONE: ABIRATERONE ACETATE: CB7630: ZYTIGA®; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; Mechanism of Action; Pharmacokinetics [2]; Mechanism of Resistance; Indications [2]; Dosages; Methods of Preparation/Administration; Special Information and Cautions [2]; Contraindications; Elderly Patients; Pediatric Patients; Renal Impairment; Hepatic Impairment; Immunisations; Warnings [2]
|
| 505 |
8 |
|
|a Mineralocorticoid ExcessAdrenocortical Insufficiency; Hepatotoxicity; Food Effect; Toxicities [2]; Dose Modifications [2]; Interactions [2]; CONCLUSION; REFERENCES; Chapter 2: ALBUMIN-BOUND (NAB) PACLITAXEL, ABRAXANE® ; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; MECHANISM OF ACTION; Pharmacokinetics; INDICATIONS; Metastatic Breast Cancer; Metastatic Pancreatic Adenocarcinoma; Dosages; METHODS OF PREPARATION/ADMINISTRATION; SPECIAL INFORMATION AND CAUTIONS; Contraindications; Elderly; Pediatric; Renal; Hepatic; Immunisations; Pregnancy; Breast-Feeding
|
| 505 |
8 |
|
|a TOXICITIES [9, 10]Dose Modifications; INTERACTIONS; CONCLUSION; REFERENCES; Chapter 3: AFLIBERCEPT. ZALTRAP®; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; MECHANISM OF ACTION; MECHANISM OF RESISTANCE; PHARMACOKINETICS [6]; INDICATIONS; DOSAGES; METHODS OF PREPARATION/ADMINISTRATION [6]; SPECIAL INFORMATION AND CAUTIONS [6]; Contraindications; Elderly Patients; Pediatric Patients; Renal Impairment; Hepatic Impairment; WARNINGS [6]; Hemorrhage; Gastrointestinal Perforation; Compromised Wound Healing; Fistula Formation; Hypertension; Arterial Thromboembolic Events
|
| 505 |
8 |
|
|a ProteinuriaNeutropenic Complications; Diarrhea and Dehydration; Pregnancy and Nursing; Immunisations; TOXICITIES; DOSE MODIFICATIONS; INTERACTIONS; CONCLUSION; REFERENCES; Chapter 4: AXITINIB. INLYTA®; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; Mechanism of Action; Pharmacokinetics [2, 3]; Mechanism of Resistance [3]; Indications; Dosage; Methods of Preparation/Administration [1]; Special Information and Cautions [1]; Contraindications; Elderly; Pediatric; Renal Impairment; Hepatic Impairment; Breast-Feeding; Pregnancy; Immunisations; Warnings [1]; Hypertension
|
| 505 |
8 |
|
|a Thromboembolic EventsHemorrhagic Events; Toxicities [1]; Dose Modifications [1]; Hepatic Impairment; Concomitant Strong CYP3A4/5 Inhibitors; Concomitant Strong CYP3A4/5 Inducers; Interactions [1]; CYP3A4/5 Inhibitors; CYP1A2 and CYP2C19 Inhibitors; CYP3A4/5 Inducers; CONCLUSION; REFERENCES; Chapter 5: BEVACIZUMAB. AVASTIN®; ABSTRACT; INTRODUCTION; DRUG CLASSIFICATION; MECHANISM OF ACTION; PHARMACOKINETICS; MECHANISM OF RESISTANCE; INDICATIONS [10]; DOSAGES [10] ; METHODS OF ADMINISTRATION/PREPARATION [10]; SPECIAL INFORMATION AND CAUTIONS [10]; Contraindications; Elderly Patients
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Cancer
|x Chemotherapy.
|
| 650 |
|
0 |
|a Clinical pharmacology.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
|
2 |
|a Antineoplastic Agents
|x pharmacology
|
| 650 |
|
2 |
|a Pharmacology, Clinical
|
| 650 |
|
2 |
|a Pharmacology
|
| 650 |
|
6 |
|a Cancer
|x Chimiothérapie.
|
| 650 |
|
6 |
|a Pharmacologie clinique.
|
| 650 |
|
6 |
|a Pharmacologie.
|
| 650 |
|
7 |
|a pharmacology.
|2 aat
|
| 650 |
|
7 |
|a HEALTH & FITNESS / Diseases / General
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Clinical Medicine
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Diseases
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Evidence-Based Medicine
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Internal Medicine
|2 bisacsh
|
| 650 |
|
7 |
|a Pharmacology.
|2 fast
|0 (OCoLC)fst01060259
|
| 650 |
|
7 |
|a Clinical pharmacology.
|2 fast
|0 (OCoLC)fst00864398
|
| 650 |
|
7 |
|a Cancer
|x Chemotherapy.
|2 fast
|0 (OCoLC)fst00845327
|
| 650 |
|
7 |
|a Antineoplastic agents.
|2 fast
|0 (OCoLC)fst00810595
|
| 655 |
|
7 |
|a Handbooks and manuals.
|2 fast
|0 (OCoLC)fst01423877
|
| 700 |
1 |
|
|a Cidon, Esther Una,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t The easy book of cancer pharmacology
|d New York : Nova Biomedical, [2016]
|z 9781634850384
|w (DLC) 2016935307
|
| 830 |
|
0 |
|a Cancer etiology, diagnosis, and treatments.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1292490
|z Texto completo
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 12933030
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL4689736
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 1292490
|
| 994 |
|
|
|a 92
|b IZTAP
|
